Medicare Expands Obesity Drug Coverage
Centers for Medicare & Medicaid Services is now detailing how Medicare recipients can access coverage for obesity medications. The expanded coverage, initially announced December 2025, makes proven obesity medicines available to millions previously unable to afford treatment.
This policy reverses a long-standing rule that barred Medicare from covering medications prescribed solely for weight loss. The change reflects a growing consensus that obesity is a chronic disease, not a lifestyle choice, and a driver of other costly conditions like heart disease and kidney failure. The new coverage is the result of a deal announced in November 2025 between the Trump administration and pharmaceutical companies Eli Lilly and Novo Nordisk. For eligible beneficiaries, this agreement caps the monthly co-payment for drugs like Wegovy and Zepbound at $50. This represents a steep discount from previous uninsured costs, which could exceed $1,000 per month. Access for Medicare Part D enrollees will be phased in. While some drug manufacturers have indicated the $50 copay could be available as early as April 2026, the Centers for Medicare & Medicaid Services (CMS) will launch a transitional "bridge" program in July 2026. This temporary measure will be in place until a more permanent pilot program, the "BALANCE Model," begins in January 2027. Coverage is not universal and is targeted at those with significant health risks. Eligibility is based on Body Mass Index (BMI) in conjunction with other conditions. For example, a person with a BMI over 27 may qualify if they also have prediabetes or cardiovascular disease. Stricter criteria apply for those with conditions like heart failure or chronic kidney disease, who may qualify with a BMI over 30. This initiative is part of a larger effort to manage prescription drug expenses for seniors. In 2026, a separate provision of Medicare Part D will cap total out-of-pocket prescription drug costs for beneficiaries at $2,100 for the year.
